Skip to main content Skip to section navigation Skip to footer
Lexaria Bioscience Corp.Lexaria BioscienceLexaria Bioscience
Lexaria Bioscience Corp.

NASDAQ:LEXX; NASDAQ WARRANT:LEXXW

  • Home
  • About
    • Management
    • Board of Directors
    • Advisors & Consultants
  • Technology
    • Overview
    • Commercial Applications
    • Research
    • Patent Portfolio
  • Licensing Opportunities
  • Investors
Contact

IR Calendar

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • 2022 Annual General Meeting
    • FAQ
  • Analyst Coverage
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Legend Removal
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents

  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

LD Micro Invitational XXII

Jun 7 – Jun 9, 2022
Webcast
Audio
  • Email Alerts
  • Contacts
  • RSS News Feed
Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

250.765.6424
info@lexariabioscience.com

Lexaria Bioscience Corp.
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

Privacy Policy

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Read More

Copyright ©2022 All rights reserved.

Back to the top